Issue 1483: March 11, 2020
TOP STORIES
IAC HANDOUTS
FEATURED RESOURCES
JOURNAL ARTICLES AND NEWSLETTERS
EDUCATION AND TRAINING
TOP STORIES
Brand new! IAC’s laminated 2020 U.S. child/adolescent and adult immunization schedules—order copies for your exam rooms today!
IAC's laminated versions of the 2020 U.S. child/adolescent immunization schedule and the 2020 U.S. adult immunization schedule are available now.
These schedules are ideal for use in any busy healthcare setting where vaccinations are given. Their tough coating can be wiped down, and they’re durable enough to stand up to a year's worth of use.
The child/adolescent schedule is eight pages (i.e., four double-sided pages) and the adult schedule is six pages (i.e., three double-sided pages), but both schedules fold down to a convenient 8.5" x 11" size.
 
With color coding for easy reading, our laminated schedules replicate the original CDC formatting, including the essential tables and notes.
PRICING
1–4 copies: $7.50 each
5–19 copies: $5.50 each
20–99 copies: $4.50 each
100–499 copies: $4.00 each
500–999 copies: $3.50 each
For quotes on customizing or placing orders of 1,000 copies or more, call 651-647-9009 or email admininfo@immunize.org
Visit the Shop IAC: Laminated Schedules web page for more information on the schedules, to view images of all the pages, to download the PDF order form, or to order online.
Related Links
Back to top
New Jersey updates its mandate for meningococcal vaccines in colleges and universities
On January 13, 2020, New Jersey passed a law updating its mandate for college students to be immunized against meningococcal disease. The new mandate requires all incoming students attending New Jersey colleges or universities to receive meningococcal vaccines in accordance with recommendations of CDC’s Advisory Committee on Immunization Practices.
New Jersey has developed a guidance document describing the broad requirement for meningococcal ACWY (MenACWY) vaccine and the targeted requirement for meningococcal serogroup B vaccine. Previously, only students residing in dormitories and attending four-year institutions were required to receive MenACWY vaccine.
The updated NJ mandate will take effect on June 15, 2020.
IAC updated its MenACWY Vaccine Mandates for Colleges and Universities web page to include the new NJ MenACWY mandate.
Related Link
- IAC’s State Laws and Mandates by Vaccine web section contains tables and maps for 13 routinely recommended vaccines. The tables and maps contain information on state immunization requirements for child care, Pre-K, schools, and colleges/universities.
Back to top
Huge milestone! IAC enrolls 500th hospital into its Hepatitis B Birth Dose Honor Roll!
On February 28, Immunization Action Coalition enrolled the St. Joseph's Hospital-South, Riverview, FL (with a birth dose coverage rate of 92%), as the 500th birthing institution into its Hepatitis B Birth Dose Honor Roll.
The Hepatitis B Birth Dose Honor Roll was launched in 2013 and is a key part of IAC’s major initiative urging the nation’s hospitals to Give Birth to the End of Hep B. Hospitals and birthing centers are recognized for attaining high coverage rates for administering hepatitis B vaccine at birth. To be included in the Hepatitis B Birth Dose Honor Roll, a birthing institution must have:
(1) reported a coverage rate of 90 percent or greater, over a 12-month period, for administering hepatitis B vaccine before hospital discharge to all newborns (including those whose parents refuse vaccination), and (2) implemented specific written policies, procedures, and protocols to protect all newborns from hepatitis B virus infection prior to hospital discharge.
IAC urges qualifying birthing institutions to apply for the Honor Roll.
Honorees are awarded an 8.5" x 11" color certificate suitable for framing and their acceptance is announced to IAC Express’s approximately 52,000 readers.
Please visit the Hepatitis B Birth Dose Honor Roll web page that lists these institutions and their exceptional efforts to protect infants from perinatal hepatitis B transmission.
Back to top
IAC Spotlight! IAC’s PowerPoint Slide Sets web page contains 13 presentations on a wide variety of immunization topics; available by request for your use
IAC's PowerPoint Slide Sets web page on immunize.org contains 13 presentations on a variety of immunization topics. These slides are available for your use "as is" or you can modify them to suit your organization's needs. Some of the slide sets include speaker’s notes. Currently the 13 slide sets are available for viewing online in a 6-slide-per-page handout format. The titles and links to the handout-formatted slides are listed below.
To request any of the PowerPoint format slide sets, go to IAC's PowerPoint Slide Sets web page. Just below the presentation's title and description, click on "Request the PowerPoint slide set" and an email request form for the PowerPoint presentation will appear. Complete the form and hit “send.” Once you have submitted your request, we will send you the presentation and, when available, the speaker’s notes. You can edit and use the slides as you see fit. If you change the slides in any way, please acknowledge that the slide set was adapted from the Immunization Action Coalition.
Visit the IAC's PowerPoint Slide Sets web page on immunize.org to access and begin utilizing these valuable slide sets today!
Back to top
CDC reports flu activity remains high, with elevated hospitalization rates among children and young adults; please continue vaccinating
Seasonal influenza activity in the United States remains high but has decreased over the past three weeks. According to CDC's Weekly U.S. Influenza Surveillance Report, FluView, rates of hospitalization among school-aged children and young adults are higher at this time than in recent seasons. Hospitalization rates among children 0–4 years old are the highest CDC has on record at this point in a season, surpassing rates reported during the second wave of the 2009 H1N1 pandemic.
Forty-eight states and Puerto Rico reported widespread activity, with Oregon and Hawaii reporting regional activity.
A total of 136 influenza-associated pediatric deaths have been reported for the 2019–20 season. Eleven influenza-associated pediatric deaths that occurred during the 2019–20 flu season were reported between weeks 51 and 9 (the weeks ending December 21, 2019, and February 29, 2020).
Influenza vaccination is recommended for everyone 6 months of age and older, so please continue to vaccinate all your patients in this age range. If you don't provide influenza vaccination in your clinic, please recommend vaccination to your patients and refer them to a clinic or pharmacy that provides vaccines or to the HealthMap Vaccine Finder to locate influenza vaccination services near them.
Related Links:
Back to top
Not-to-miss immunization articles in the news
Three articles that appeared in the media recently are particularly compelling in conveying the potential risks of vaccine-preventable diseases and the importance of vaccination.
Back to top
Stay up to date on the latest coronavirus information from CDC and WHO
CDC and WHO are closely monitoring outbreaks of respiratory illness caused by a novel coronavirus (COVID-19). Be sure to check the resources below for the latest information, and stay in touch with your state health department.
Related Links:
Back to top
IAC HANDOUTS
IAC updates both of its standing orders templates for administering MenACWY vaccine—one for children/teens and the other for adults
IAS has updated both of its standing orders templates for administering the MenACWY vaccine: Standing Orders for Administering Meningococcal ACWY Vaccine to Children and Teens and Standing Orders for Administering Meningococcal ACWY Vaccine to Adults. A small edit was made to both templates in section #1 to add a second complement inhibitor (ravulizumab, Ultomiris; Alexion), which blocks terminal complement activation and may increase risk of encapsulated bacterial infections.
Related Links:
Back to top
IAC updates “Meningococcal ACWY Vaccine Recommendations by Age and Risk Factor”
IAC recently updated Meningococcal ACWY Vaccine Recommendations by Age and Risk Factor. A small edit was made in footnote #9 to add a second complement inhibitor (ravulizumab, Ultomiris; Alexion), which blocks terminal complement activation and may increase risk of encapsulated bacterial infections.
Related Links:
Back to top
IAC updates a technical piece for healthcare professionals titled “Meningococcal B Vaccine: IAC Answers Your Questions”
IAC updated Meningococcal B Vaccine: IAC Answers Your Questions, a technical piece with information about shared clinical decision making, MenB booster doses for patients at increased risk, and to add a second complement inhibitor (ravulizumab, Ultomiris; Alexion), which blocks terminal complement activation and may increase risk of encapsulated bacterial infections.
Related Links:
Back to top
IAC updates its piece for the general public “Meningococcal: Questions and Answers—Information about the Disease and Vaccines”
IAC has updated Meningococcal: Questions and Answers—Information about the Disease and Vaccines. Changes were made to reflect the updated ACIP recommendation to use shared clinical decision-making for patients ages 16 through 23 years, to incorporate the recommendations for booster doses for patients at increased risk, to add a second complement inhibitor (ravulizumab, Ultomiris; Alexion), which blocks terminal complement activation and may increase risk of encapsulated bacterial infections.
Related Links:
Back to top
FEATURED RESOURCES
CDC updates recommendations in its “General Best Practice Guidelines for Immunization”
CDC has recently updated its General Best Practice Guidelines for Immunization with several changes. The General Best Practice Guidelines’ List of Errata/Updates web page provides a list of all errata and updates that have been made and the dates the changes were made. The list is updated whenever it is determined changes are necessary.
The page numbers correspond to the version in PDF format.
- Page 23: The recommendation was changed to allow providers to administer a dose of live, injectable vaccine, even if the interval after an antibody-containing blood product is not complete, to induce active protection. Even so, the dose should not count toward needed doses and should be repeated. Serology is no longer recommended to ascertain whether the dose provided protection.
- Page 39 (Table 3-5 Footnotes): The specific source material for understanding antibody quantities in antibody products is now listed. Also listed is the process for determining how to calculate the interval between antibody product and live, injectable vaccine, based on the quantity of antibody in the product.
- Page 55 (Table 4-1): A footnote is placed after HPV vaccine to clarify that HPV vaccine is not recommended during pregnancy.
- Page 115: For response to out-of-range temperature readings, if a non-live vaccine is administered and then found out to have been stored at a deviated temperature, the dose should be repeated and does not need to wait an interval from the invalid dose. An exception to this rule is zoster recombinant vaccine (RZV, Shingrix; GSK), which is a non-live vaccine; such an RZV dose needs to be repeated and does need to wait 4 weeks after the invalid dose.
Related Links
Back to top
CDC releases new patient handout “Talking to Pregnant Women About Vaccines”
CDC released a new handout for patients titled Talking to Pregnant Women About Vaccines to help answer common questions about the use of vaccines during pregnancy.
It’s part of CDC’s Toolkit for Prenatal Care Providers which is designed to help ob-gyns, family physicians, and nurse midwives increase rates of maternal immunization.
Related Links
Back to top
JOURNAL ARTICLES AND NEWSLETTERS
“Maximizing the Impact of, and Sustaining Standing Orders Protocols for Adult Immunization in Outpatient Clinics” published in American Journal of Infection Control
American Journal of Infection Control published Maximizing the Impact of, and Sustaining Standing Orders Protocols for Adult Immunization in Outpatient Clinics, by Tan LJ, et al., in its March issue. The conclusion is reprinted below.
SOPs may provide a good starting point for increasing adult immunization coverage rates. Using additional interventions, quality-based metrics, or incentives could lead to sustained adult immunization prioritization.
Access the full article in PDF format.
Back to top
“Combating Vaccine Hesitancy and Other 21st Century Social Determinants in the Global Fight Against Measles” published in Science Direct
Science Direct published Combating Vaccine Hesitancy and Other 21st Century Social Determinants in the Global Fight Against Measles by Hotez PJ, et al., in its April issue. Key portions of the abstract are reprinted below.
Measles transmission due to sharp declines in measles-mumps-rubella (MMR) vaccination coverage is now widespread among nations that previously saw impressive public health gains including Philippines, DR Congo, Madagascar, Samoa, many in Europe, and the United States and Venezuela in the Americas. Key determinants include the interruption of vaccine health systems due to war, conflict, and political instability; food insecurity and urbanization; and an increasingly globalized vaccine hesitancy or antivaccine movement. Vaccine hesitancy is partly responsible for over 100 000 measles cases in Europe in 2019, and the re-emergence of measles to the United States almost twenty years after it was eliminated. Three major elements currently comprise the American antivaccine movement, including a media empire, a political arm, and deliberate predatory behavior.
Access the full article in PDF format.
Back to top
EDUCATION AND TRAINING
GSA's "Elevating Understanding of RSV in Older Adults" webinar to be held March 31
Mark your calendar for Gerontological Society of America's Elevating Understanding of RSV in Older Adults webinar on March 31 at 12:00 p.m. (ET). Scroll down the GSA web page for details.
Respiratory syncytial virus, or RSV, causes 177,000 hospitalizations and 14,000 deaths in older adults each year. In this 1-hour webinar, experts will share what is known about the prevalence, incidence, and impact of RSV in older adults.
There is no charge for this webinar. To register, you will need to follow the registration instructions and create a free account.
Back to top
|
|
